220 related articles for article (PubMed ID: 29410031)
1. Intraperitoneal administration of aluminium-based adjuvants produces severe transient systemic adverse events in mice.
Freiberger SN; Leuthard DS; Duda A; Contassot E; Thallmair M; Kündig TM; Johansen P
Eur J Pharm Sci; 2018 Mar; 115():362-368. PubMed ID: 29410031
[TBL] [Abstract][Full Text] [Related]
2. [Aluminum as an adjuvant in vaccines and post-vaccine reactions].
Fiejka M; Aleksandrowicz J
Rocz Panstw Zakl Hig; 1993; 44(1):73-80. PubMed ID: 8235346
[TBL] [Abstract][Full Text] [Related]
3. Adverse events after immunisation with aluminium-containing DTP vaccines: systematic review of the evidence.
Jefferson T; Rudin M; Di Pietrantonj C
Lancet Infect Dis; 2004 Feb; 4(2):84-90. PubMed ID: 14871632
[TBL] [Abstract][Full Text] [Related]
4. Using bicistronic IL-4 reporter mice to identify IL-4 expressing cells following immunisation with aluminium adjuvant.
McDonald F; Mohrs M; Brewer J
Vaccine; 2006 Jun; 24(26):5393-9. PubMed ID: 16630673
[TBL] [Abstract][Full Text] [Related]
5. Sequestering of damage-associated molecular patterns (DAMPs): a possible mechanism affecting the immune-stimulating properties of aluminium adjuvants.
Svensson A; Sandberg T; Siesjö P; Eriksson H
Immunol Res; 2017 Dec; 65(6):1164-1175. PubMed ID: 29181774
[TBL] [Abstract][Full Text] [Related]
6. On vaccine's adjuvants and autoimmunity: Current evidence and future perspectives.
Pellegrino P; Clementi E; Radice S
Autoimmun Rev; 2015 Oct; 14(10):880-8. PubMed ID: 26031899
[TBL] [Abstract][Full Text] [Related]
7. [Aluminium adjuvant exposure through vaccines in France in 2018].
Angrand L; Elnar AA; Authier FJ; Gherardi RK; Crépeaux G
Ann Pharm Fr; 2020 Mar; 78(2):111-128. PubMed ID: 32081303
[TBL] [Abstract][Full Text] [Related]
8. When an aluminium adjuvant is not an aluminium adjuvant used in human vaccination programmes.
Exley C
Vaccine; 2012 Mar; 30(12):2042. PubMed ID: 22041301
[No Abstract] [Full Text] [Related]
9. Aluminium-adjuvanted vaccines--a review of the current state of knowledge.
Gołoś A; Lutyńska A
Przegl Epidemiol; 2015; 69(4):731-4, 871-4. PubMed ID: 27139352
[TBL] [Abstract][Full Text] [Related]
10. The global impact of vaccines containing aluminium adjuvants.
Clements CJ; Griffiths E
Vaccine; 2002 May; 20 Suppl 3():S24-33. PubMed ID: 12184361
[TBL] [Abstract][Full Text] [Related]
11. Adjuvants and autoimmunity.
Israeli E; Agmon-Levin N; Blank M; Shoenfeld Y
Lupus; 2009 Nov; 18(13):1217-25. PubMed ID: 19880572
[TBL] [Abstract][Full Text] [Related]
12. Reviewing the association between aluminum adjuvants in the vaccines and autism spectrum disorder.
Boretti A
J Trace Elem Med Biol; 2021 Jul; 66():126764. PubMed ID: 33930617
[TBL] [Abstract][Full Text] [Related]
13. Aluminium compounds for use in vaccines.
Lindblad EB
Immunol Cell Biol; 2004 Oct; 82(5):497-505. PubMed ID: 15479435
[TBL] [Abstract][Full Text] [Related]
14. A role for the body burden of aluminium in vaccine-associated macrophagic myofasciitis and chronic fatigue syndrome.
Exley C; Swarbrick L; Gherardi RK; Authier FJ
Med Hypotheses; 2009 Feb; 72(2):135-9. PubMed ID: 19004564
[TBL] [Abstract][Full Text] [Related]
15. Uric acid and the vaccine adjuvant activity of aluminium (oxy)hydroxide nanoparticles.
Thakkar SG; Xu H; Li X; Cui Z
J Drug Target; 2018; 26(5-6):474-480. PubMed ID: 29334279
[TBL] [Abstract][Full Text] [Related]
16. [Post-vaccination granulomas caused by delayed-type reaction to aluminum salts].
Wahl RU; Wurpts G; Merk HF
Hautarzt; 2014 May; 65(5):384-6. PubMed ID: 24736873
[TBL] [Abstract][Full Text] [Related]
17. Inflammatory responses following intramuscular and subcutaneous immunization with aluminum-adjuvanted or non-adjuvanted vaccines.
Kashiwagi Y; Maeda M; Kawashima H; Nakayama T
Vaccine; 2014 Jun; 32(27):3393-401. PubMed ID: 24768634
[TBL] [Abstract][Full Text] [Related]
18. [Aluminium allergy and granulomas induced by vaccinations for children].
Andersen RM; Zachariae C; Johansen JD
Ugeskr Laeger; 2015 Apr; 177(18):868-71. PubMed ID: 26539576
[TBL] [Abstract][Full Text] [Related]
19. [Aluminium allergy and granulomas induced by vaccinations for children].
Andersen RM; Zachariae C; Johansen JD
Ugeskr Laeger; 2014 Mar; 176(12A):. PubMed ID: 25350883
[TBL] [Abstract][Full Text] [Related]
20. A role for impaired regulatory T cell function in adverse responses to aluminum adjuvant-containing vaccines in genetically susceptible individuals.
Terhune TD; Deth RC
Vaccine; 2014 Sep; 32(40):5149-55. PubMed ID: 25066736
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
